Depomed Makes Last Ditch Plea To Shareholders

Depomed reiterated its opposition to the Horizon Pharma acquisition, reminding its shareholders in a letter that the company believes it is being undervalued and that the Nucynta franchise holds greater value than the deal.

Days after Horizon commenced its tender offer for the outstanding shares of Depomed -- taking its hostile offer straight to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip